Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage
biopharmaceutical company focused on improving the
intracellular delivery of nucleic acids and small molecules with
its lipid nanocrystal (LNC) platform technology, announced today
that Jerome D. Jabbour, Chief Executive Officer of Matinas
BioPharma, will present at the H.C. Wainwright 24th Annual Global
Investment Conference on Tuesday, September 13, 2022, at 1:30 p.m.
ET, and host investor meetings. The conference is being held at the
Lotte New York Palace Hotel in New York City.
Investors interested in arranging a meeting with
the Company’s management during the conference should contact the
H.C. Wainwright conference coordinator. A webcast of the
presentation will be available on the IR Calendar page of
the Investors section of the Company’s website
(www.matinasbiopharma.com) following the event for 90 days.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company
focused on improving the intracellular delivery of nucleic acids
and small molecules with its lipid nanocrystal (LNC) platform
technology. The Company is developing its own internal portfolio of
products as well as partnering with leading pharmaceutical
companies to develop novel formulations that capitalize on the
unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated
that this novel technology can provide solutions to many of the
challenges in achieving safe and effective intracellular delivery,
for both small molecules and larger, more complex molecules, such
as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines.
The combination of a unique mechanism of action and flexibility
with formulation and route of administration (including oral),
positions Matinas’ LNC technology to potentially become the
preferred next-generation intracellular drug delivery vehicle with
distinct advantages over both lipid nanoparticles and viral
The Company is focused on developing an internal
and external pipeline of drugs candidates based on the LNC
platform. Internally, the Company has two clinical stage assets.
MAT2203 is an oral, LNC formulation of the highly potent antifungal
medicine amphotericin B, currently planning for a Phase 3
registration trial; MAT2501 is an oral, LNC formulation of the
broad-spectrum aminoglycoside, amikacin, primarily used to treat
chronic and acute bacterial infections, and currently in Phase 1.
Externally, the Company has established a broad set of
relationships with multiple global pharmaceutical collaborators,
including BioNTech (mRNA), the National Institutes of Health and
Gilead Sciences (antivirals), and Genentech, a member of the Roche
Group (small molecules, antisense oligonucleotides, and antibody
For more information, please visit
Forward Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to our business
activities, our strategy and plans, our collaboration with
BioNTech, the potential of our LNC platform delivery technology,
and the future development of its product candidates, the Company’s
ability to identify and pursue development, licensing and
partnership opportunities for its products or platform delivery
technology on favorable terms, if at all, and the ability to obtain
required regulatory approval and other statements that are
predictive in nature, that depend upon or refer to future events or
conditions. All statements other than statements of historical fact
are statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to protect the
Company’s intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company’s products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma’s product candidates are all in a
development stage and are not available for sale or use.
Investor and Media Contact
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Jan 2023 to Feb 2023
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Feb 2022 to Feb 2023